ArticleScientific reports2025
Lightweight Vision Transformer with transfer learning for interpretable Alzheimer's disease severity assessment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early and reliable diagnostic tools are critical for slowing the progression of Alzheimer's disease (AD), a neurodegenerative disorder characterized by memory loss and cognitive decline. This study introduces, ViTTL, lightweight deep learning framework for assessing the severity of AD using MRI data. ViTTL integrates Vision Transformers (ViT) with pre-trained convolutional neural networks utilized in transfer learning mode, to extract informative features from 2D MRI slices. Among the evaluated combinations, the ViT-DenseNet201 model integrated with an artificial neural network (ANN) classifier achieved the highest classification accuracy (99.89%) on the OASIS dataset. To ensure interpretability, we incorporated LIME and GRAD-CAM method, which consistently focus on cortical and hippocampal regions known to be associated with Alzheimer's pathology. The average Dice similarity coefficient across runs was 0.85 with a standard deviation of 0.03, indicating high consistency in the model's focus regions against ground truth annotations by expert radiologists. ViTTL also achieved a substantial reduction in model size from 83.0 MB to 6.47 MB enabling deployment in resource-limited environments without compromising performance. Validation on an independent dataset (Kaggle) and comparative performance analysis against state-of-the-art methods further support the robustness and generalizability. These findings demonstrate that ViTTL is a promising tool for accurate, interpretable, and resource-efficient AD diagnosis, with strong potential for clinical translation and patient outcome improvement. The related codes are available at https://github.com/RuhikaSharma/enhanced-alzheimer-risk-assessment .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.